Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
12 hedge funds and large institutions have $228K invested in Evoke Pharma in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 12 closing their positions.
129% more call options, than puts
Call options by funds: $39K | Put options by funds: $17K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
3.96% less ownership
Funds ownership: 6.07% → 2.11% (-4%)
40% less funds holding
Funds holding: 20 → 12 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
77% less capital invested
Capital invested by funds: $987K → $228K (-$759K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.96K |
| 4 |
Citigroup
New York
|
+$3.24K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$2.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$245K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$54K |
| 3 |
State Street
Boston,
Massachusetts
|
-$41K |
| 4 |
CC
Cornerstone Capital
Palo Alto,
California
|
-$33K |
| 5 |
BlackRock
New York
|
-$25.8K |
EVOK Hedge Fund Activity: Q2 2022 in Review
12 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2022, worth a combined $228K — down 77% from $987K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of EVOK and 4 opened new positions — a net loss of 8 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $14.5K. The largest seller was Vanguard Group, cutting an estimated $245K.
- 12 institutional investors held Evoke Pharma (EVOK) as of Q2 2022, down from 20 in Q1 2022.
- Funds reported $228K of Evoke Pharma stock for Q2 2022, down 77% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q2 2022 and 12 closed out, a net change of -8 holders.
- The largest Evoke Pharma buyer in Q2 2022 was UBS Group, an estimated $14.5K added.
- The largest Evoke Pharma seller in Q2 2022 was Vanguard Group, an estimated $245K sold.
Based on aggregated 13F filings for Q2 2022.